- Home
- MDCX vs LSTA Comparison
MDCX vs LSTA Comparison
Compare MDCX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- LSTA
- Stock Information
- Founded
- MDCX 2008
- LSTA 1980
- Country
- MDCX Canada
- LSTA United States
- Employees
- MDCX N/A
- LSTA N/A
- Industry
- MDCX
- LSTA Misc Health and Biotechnology Services
- Sector
- MDCX
- LSTA Health Care
- Exchange
- MDCX Nasdaq
- LSTA Nasdaq
- Market Cap
- MDCX 33.8M
- LSTA 31.2M
- IPO Year
- MDCX N/A
- LSTA N/A
- Fundamental
- Price
- MDCX $4.00
- LSTA $2.55
- Analyst Decision
- MDCX Strong Buy
- LSTA Strong Buy
- Analyst Count
- MDCX 1
- LSTA 1
- Target Price
- MDCX $10.00
- LSTA $15.00
- AVG Volume (30 Days)
- MDCX 41.4K
- LSTA 24.3K
- Earning Date
- MDCX 01-01-0001
- LSTA 02-27-2025
- Dividend Yield
- MDCX N/A
- LSTA N/A
- EPS Growth
- MDCX N/A
- LSTA N/A
- EPS
- MDCX N/A
- LSTA N/A
- Revenue
- MDCX N/A
- LSTA N/A
- Revenue This Year
- MDCX N/A
- LSTA N/A
- Revenue Next Year
- MDCX N/A
- LSTA N/A
- P/E Ratio
- MDCX N/A
- LSTA N/A
- Revenue Growth
- MDCX N/A
- LSTA N/A
- 52 Week Low
- MDCX $1.80
- LSTA $2.19
- 52 Week High
- MDCX $4.39
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- LSTA 42.39
- Support Level
- MDCX N/A
- LSTA $2.41
- Resistance Level
- MDCX N/A
- LSTA $2.66
- Average True Range (ATR)
- MDCX 0.00
- LSTA 0.19
- MACD
- MDCX 0.00
- LSTA 0.01
- Stochastic Oscillator
- MDCX 0.00
- LSTA 42.06
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.